ICER

Key TakeawaysICER to evaluate apitegromab and new evidence for SMA treatments. Public comments on the Draft Scoping Document are open until January 27,...

Key TakeawaysICER's fourth annual report highlights notable progress in aligning drug coverage policies with fair access standards. Transparency in coverage policy information and...

Key TakeawaysICER highlights five drugs with unsupported price increases in 2023. These increases cost the US healthcare system $815 million in excess spending. ...

Key TakeawaysICER releases a draft evidence report on suzetrigine for acute pain treatment. Public comments are open until January 13, 2025, with a...

Key TakeawaysTabelecleucel shows clinical benefits for relapsed/refractory EBV+ PTLD patients. ICER's assessment highlights unmet needs and potential cost-effectiveness thresholds. Pricing benchmarks are set...

Key TakeawaysICER will evaluate the clinical effectiveness and value of tolebrutinib for Secondary Progressive MS (SPMS). The assessment will be presented at the...

Key TakeawaysICER’s report confirms that tafamidis, acoramidis, and vutrisiran provide significant health benefits for transthyretin amyloid cardiomyopathy (ATTR-CM). ICER suggests pricing tafamidis and...

The rapid response report by the Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) suggests a major leap forward in preeclampsia screening. By...

Key TakeawaysThe next round is expected to target COPD drugs like GSK's Breo Ellipta and Trelegy Ellipta. ICER is preparing a special report...

Key TakeawaysICER to assess the value and effectiveness of sonpiretigene isteparvovec for retinitis pigmentosa. Public comments on the Draft Scoping Document are open...

Key TakeawaysICER released a draft evidence report assessing the effectiveness and value of tabelecleucel for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease. Public...

The Institute for Clinical and Economic Review (ICER) released important findings related to treatments in the field of anemia for myelodysplastic syndrome (MDS). These...

Key Takeaways:ICER evaluates tafamidis, acoramidis, and vutrisiran for treating transthyretin amyloid cardiomyopathy (ATTR-CM). Tafamidis and acoramidis offer health benefits at a cost-effective price...

Key Takeaways:ICER's final evidence report indicates that the current pricing of imetelstat does not align with its modest clinical benefits in treating anemia...

This month, the Institute for Clinical and Economic Review (ICER) has released several important reports and updates. These publications highlight ICER's dedication to assessing...